KPC Pharmaceuticals,Inc.'s (SHSE:600422) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Simply Wall StDec 12 00:30 ET

KPC Pharmaceuticals' Unit Gets Nod to Add Indications for Colchicine Tablets

MT NewswiresNov 29 05:15 ET

KPC Pharmaceuticals Gets China Clinical Trial Approval for Fatty Liver Drug

MT NewswiresNov 25 01:59 ET

kpc pharmaceuticals, inc. (600422.SH): Received a notice of approval for drug clinical trials.

Gelonghui November 22nd | kpc pharmaceuticals, inc. (600422.SH) announced that the company recently received the KPC000154 tablet issued by the State Food and Drug Administration (Notice Number: 2024LP02631, 2024LP02632, hereinafter referred to as "the new drug") in accordance with the Category 1 New Drug Acceptance "Drug Clinical Trial Approval Notice", allowing the new drug to conduct related clinical trials. Research, KPC000154 tablets for the treatment of Nonalcoholic steatohepatitis (NASH).

Gelonghui FinanceNov 22 04:13 ET

chinares pharma (03320): china resources sanjiu medical & pharmaceutical (000999.SZ) will sell 51% of its stake in Kunshan Pharmaceutical (600422.SH).

Chinares pharma (03320) issued an announcement that on November 21, 2024, china resources sanjiu medical & pharmaceutical and Kunming Pharma entered into a share transfer agreement...

Zhitong FinanceNov 21 05:23 ET

zhongtai: In Q3 2024, traditional chinese medicine companies are experiencing temporary pressure, while end demand has slightly rebounded.

In the third quarter of 2024, traditional chinese medicine companies are experiencing temporary performance pressure, but gross margin is expected to improve upward from 2025.

Zhitong FinanceNov 20 01:06 ET